Orphan Drug Approvals of 2015: Europe and the United States
Authors:
- Peter NormanPNPeter Norman
- 11 April 2016
- journal article
- Published by Informa Healthcare in Expert Opinion on Orphan Drugs
- Vol. 4 (5) , 491-500
Abstract
No abstract availableKeywords
This publication has 59 references indexed in Scilit:
- A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid CancerClinical Cancer Research, 2016
- Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine‐refractory differentiated thyroid cancerCancer Science, 2015
- Best Practices in Adolescent and Young Adult Patients with Acute Lymphoblastic Leukemia: A Focus on AsparaginaseJournal of Adolescent and Young Adult Oncology, 2015
- Orphan drug approvals of 2014: Europe and the United StatesExpert Opinion on Orphan Drugs, 2015
- Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic LeukemiaJournal of Clinical Oncology, 2014
- Use of Statins and the Risk of Death in Patients With Prostate CancerJournal of Clinical Oncology, 2014
- Pediatric Acute Lymphoblastic Leukemia: Efficacy and safety of recombinant E. coli-asparaginase in infants (less than one year of age) with acute lymphoblastic leukemiaHaematologica, 2013
- CarfilzomibBlood, 2013
- Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for NeuroblastomaNew England Journal of Medicine, 2010
- Multi-Kinase Inhibitor E7080 Suppresses Lymph Node and Lung Metastases of Human Mammary Breast Tumor MDA-MB-231 via Inhibition of Vascular Endothelial Growth Factor-Receptor (VEGF-R) 2 and VEGF-R3 KinaseClinical Cancer Research, 2008